Tweets

🤨To cycle or not to cycle TNFi. Abst#0585 studied pts with PsA and axSpA with primary TNFi failure: -Switching to IL17Ai may benefit phGA for arthritis and psoriasis in PsA pts and fatigue in axSpA pts. @AlexisOgdie #ACR24 @RheumNow https://t.co/Jc0cdmrVhI

Links:

Adela Castro @AdelaCastro222 ( View Tweet )
1 year 2 months ago
Can PROs help identify high-risk #SLE patients? #Abstract0655 from the FORWARD registry shows higher SLAQ scores (including flares) and RDCI are linked to increased hospitalization risk. @RheumNow #ACR24

Akhil Sood MD @AkhilSoodMD ( View Tweet )

1 year 2 months ago
Abstract 0587: Among PsA patients (bDMARD-naive & TNF non-responders) treated with Bimekizumab, better disease control was linked to improved work productivity, including ↓ work impairment, ↓ presenteeism, and ↓ activity impairment. #ACR24 @RheumNow https://t.co/sZBjJ9lk39

Links:

Akhil Sood MD @AkhilSoodMD ( View Tweet )
1 year 2 months ago

TAPIR study of continuing vs stopping steroids in ANCA vasculitis in remission. Relapse at month 6 in 16% vs 4%. OR 4.22, but low rate in either group. If treated Rituximab, no difference! Merkel et al. @RheumNow #ACR24 Abstr#0774 #ACRbest https://t.co/pKa4U5L2fW https://t.co/MjzE14SeGi

Links:

Richard Conway @RichardPAConway ( View Tweet )
1 year 2 months ago
Happening now: 16S18 Into the Weeds: Cannabis in Rheum @EleniTiniakou @BharatKumarMD Do you discuss marijuana with your patients? @RheumNow #ACR24

Eric Dein @ericdeinmd ( View Tweet )

1 year 2 months ago
Ashgar et al. Metformin reduces risk of TKR in T2DM with OA in meta-analysis. RR 0.59 @RheumNow #ACR24 Abstr#0029 https://t.co/OhqTJZQwKX https://t.co/RTQUjE6lLy

Links:

Richard Conway @RichardPAConway ( View Tweet )
1 year 2 months ago
Abstr#0647 Toronto Lupus Clinic finds pericarditis in 20% of #SLE inception cohort, often with skin, heme, MSK, & renal involvement. Linked to younger age, White race, +SSB, & lower ACR/EULAR scores - Tx: GC, HCQ, AZA @RheumNow #ACR24

Akhil Sood MD @AkhilSoodMD ( View Tweet )

1 year 2 months ago
Abstract #0614 What is the impact of Lupus on my quality of life? Consider using Lupus Impact Tracker (https://t.co/fJQe2uHicM) - high dose GC, comorbidities, and not actively working associated with worse impact on QoL - HCQ shows benefit @RheumNow #ACR24

Links:

Akhil Sood MD @AkhilSoodMD ( View Tweet )

1 year 2 months ago
#0477 🌍 Global prevalence of RA-ILD ➡️21.38% (95% CI 0.15 - 0.29),33 studies, n=14,281 🔬 Higher RA-ILD risk in smokers, low-income regions, DMARD use. ⛔️Wide CI = heterogeneity main limitation 💡 Screening & lifestyle changes key for high-risk groups. #ACR24 @RheumNow

Caoilfhionn Connolly @CaoilfhionnMD ( View Tweet )

1 year 2 months ago
Harnessing power of AI in Rheumatology. Strengths and weaknesses of AI will need to be assessed. Amanda Nelson shares the limitation of AI @RheumNow #ACR24 https://t.co/G8FNVco7Qp

Links:

Antoni Chan MD (Prof) @synovialjoints ( View Tweet )
1 year 2 months ago

A study in difficult-to-treat (D2T) ankylosing spondylitis (AS) reveals distinct characteristics in patients, including: - Higher BMI - Increased comorbidities - Presence of EAMs - HLA-B27 positivity is linked to higher odds of being D2T, highlighting potential genetic… https://t.co/XcShdxSwhm

Links:

Antoni Chan MD (Prof) @synovialjoints ( View Tweet )

1 year 2 months ago
Data from the EISER study show that IBD was significantly more prevalent in pts with r-axSpA than nr-axSpA. Makes sense in a way since longer dse duration may play a role. 🔶️THM - screen SpA pts for IBD; ask for GI symptoms @RheumNow #ACR24 abs554 https://t.co/Q6jeDUFa8Z

Links:

sheila @RHEUMarampa ( View Tweet )
1 year 2 months ago
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×